[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jung-min Ahn\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":107},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100568058","phase-4-aspirin-use-and-statin-strategy-for-primary-prevention-in-severe-coronary-calcium-score-on-computed-tomography-100568058",false,"NCT06676280","ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography","an Investigator-initiated, Multicenter, Open-label, 2-by-2 Factorial, and Randomized Trial to Evaluate the Role of Aspirin and High-intensity Statin Therapy, Respectively, in Individuals With Severe Coronary Calcification (Coronary Calcium Score ≥300) to Prevent Atherosclerotic Cardiovascular Disease (ASCVD) Events With Severe Coronary Calcification (CAC ≥300)","ASA-3C","Inclusion Criteria:\n\n1. The subject must be aged between 40 and 75 years.\n2. Patients who have coronary artery calcium score ≥300 Agatston Unit on coronary calcium computed tomography.\n3. Patients who have 1 or more CVD risk factors in below;\n\n   * dyslipidemia or,\n   * diabetes or,\n   * hypertension or,\n   * family history of CVD or,\n   * smoking\n4. Patients agree to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthical Committee of the respective clinical site.\n\nExclusion Criteria:\n\n1. Individuals who have symptomatic coronary artery disease or heart failure.\n2. Patients who have documented clinical Atherosclerotic Cardiovascular Disease: previous myocardial infarction, acute coronary syndrome, stable angina, coronary revascularization and other arterial revascularization procedures, stroke and Transient ischaemic attack (TIA), \\>50% carotid stenosis or previous carotid endarterectomy or stenting, aortic aneurysm and peripheral artery disease.\n3. Patients who have evidence of myocardial ischemia on non-invasive stress test including stress single photon emission CT myocardial perfusion imaging (SPECT MPI), cardiovascular magnetic resonance (CMR) imaging, stress echocardiography, or treadmill test, or on invasive stress test including Fractional flow reserve (FFR) \\\u003C 0.80 on invasive coronary angiography (diameter stenosis\\>50% without objective evidence of ischemia could be enrolled).\n4. Patients at high risk of bleeding: gastrointestinal hemorrhage or peptic ulcer within the previous 6 months; active hepatic disease such as cirrhosis or active hepatitis; use of warfarin, or other anticoagulant therapy; or has a history of aspirin allergy.\n5. Patients with atrial fibrillation and flutter.\n6. Patients with severe left ventricular dysfunction (ejection fraction ≤30%) or severe valvular heart disease who experience dyspnea on exertion (The NYHA (New York Heart Association) Functional Classification III-IV).\n7. History of allergy or severe adverse reaction to aspirin or statin or ezetimibe.\n8. History of myositis or myopathy with active disease in the 180 days prior to study entry.\n9. Patients with active liver disease or persistent unexplained serum transaminase elevation.\n10. Patients who have significantly abnormal findings which identified violation for safety by investigator on physical examination, blood test and electrocardiogram.\n11. History of alcohol or drug abuse.\n12. Concurrent medical condition with a life expectancy of less than 1 years.\n13. Pregnant and\u002For lactating women.\n14. Patient was unable to provide written informed consent or participate in log-term follow up.","ALL","40 Years","75 Years",{"count":21,"type":22},5000,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The primary objective of the ASA-3C trial is to evaluate the role of aspirin and high-intensity statin therapy, respectively, in individuals with severe coronary calcification (coronary calcium score ≥300) to prevent atherosclerotic cardiovascular disease (ASCVD) events with severe coronary calcification (CAC ≥300).",[28],"Cardiovascular Diseases",[30,31,32],"atherosclerotic cardiovascular disease","aspirin","high-intensity statin","RECRUITING","2026-06-30",{"date":36,"type":37},"2026-07-01","ACTUAL",{"date":39,"type":37},"2025-07-24",{"date":41,"type":22},"2035-12-31",{"name":43,"class":44},"Jung-min Ahn","OTHER",32,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100636469","noninferiority-trial-of-sirolimus-with-ascorbic-acid-versus-everolimus-in-all-comers-100636469","NCT07566091","Noninferiority Trial Of Sirolimus With Ascorbic Acid Versus Everolimus in All-comers","NOVA","Inclusion Criteria:\n\n1. Adult men and women aged 19 years or older\n2. Patients with chronic coronary syndrome (CCS) or acute coronary syndrome (ACS) who require percutaneous coronary intervention (PCI) (all-comers)\n3. Patients who have voluntarily provided written informed consent to participate in the study\n\nExclusion Criteria:\n\n1. Cardiogenic shock within 48 hours prior to the procedure\n2. Known hypersensitivity to sirolimus, everolimus, ascorbic acid, or stent components (e.g., cobalt-chromium alloy)\n3. Patients unable to maintain dual antiplatelet therapy (DAPT), including aspirin and a P2Y12 inhibitor, for 1 year\n4. Women who are pregnant, breastfeeding, or of childbearing potential\n5. Clinically significant abnormalities identified during study visits, physical examination, laboratory tests, or electrocardiogram (ECG) that, in the investigator's judgment, may interfere with the safe completion of the study\n6. Life expectancy of less than 1 year or presence of serious non-cardiac conditions that may affect compliance with the study protocol\n7. Patients who are unwilling or unable to comply with the study protocol","19 Years",{"count":55,"type":22},2034,[57],"NA","The objective of this study is to demonstrate the primary hypothesis that, in patients with chronic and acute coronary syndromes requiring percutaneous coronary intervention (PCI), the novel sirolimus-ascorbic acid eluting stent (D+Storm Novonix) is non-inferior to the standard treatment, the everolimus-eluting stent (Synergy XD), with respect to the incidence of target lesion failure (TLF) at 1 year after treatment, where TLF is defined as a composite of cardiovascular death, target vessel myocardial infarction, and clinically driven target-lesion revascularization.",[60],"Coronary Artery Disease",[62,63,64,65,66,67],"acute coronary syndrome","chronic coronary syndrome","D+Storm Novonix","sirolimus-ascorbic acid eluting stent","everolimus-eluting stent","percutaneous coronary intervention","NOT_YET_RECRUITING","2026-04-27",{"date":71,"type":37},"2026-05-04",{"date":73,"type":22},"2026-06-15",{"date":75,"type":22},"2028-06-15",{"name":43,"class":44},1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":86,"targetDuration":88,"studyType":89,"phases":4,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},"100442660","evaluation-of-effectiveness-and-safety-of-synergy-xd-and-synergy-megatron-stent-100442660","NCT05044273","Evaluation of Effectiveness and Safety of Synergy XD and Synergy Megatron™ Stent","Evaluation of Effectiveness and Safety of Synergy™ XD Stent and Synergy Megatron™ Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study","IRIS SynergyXD","Inclusion Criteria:\n\n* Patients ≥ 19 years old\n* Patients receiving Synergy XD stent(s) or Synergy Megatron™ stent(s).\n* The patient or guardian agrees to the study protocol and the schedule of clinical follow-up and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthics Committee of the respective clinical site.\n\nExclusion Criteria:\n\n* Patients with a mixture of other drug-eluting stents (DESs)\n* Terminal illness with life-expectancy ≤1 year.\n* Patients with cardiogenic shock",{"count":87,"type":22},2000,"5 Years","OBSERVATIONAL","The objective of this study is to evaluate the effectiveness and safety of Synergy XD stent and Synergy Megatron™ Stent in the \"real world\" daily practice as compared with the other drug-eluting stents.",[60,28,92,93,94],"Heart Diseases","Myocardial Ischemia","Coronary Disease",[96,67,97],"drug eluting stent","real world","2025-12-21",{"date":100,"type":37},"2025-12-29",{"date":102,"type":37},"2022-09-01",{"date":104,"type":22},"2031-12-31",{"name":43,"class":44},23,""]